In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivative
about
In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacinIn vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinoloneAntimicrobial activity of Ro 23-9424, a novel ester-linked codrug of fleroxacin and desacetylcefotaxime.In vitro and in vivo antibacterial activities of T-3262, a new fluoroquinolone.Renal handling of fleroxacin in rabbits, dogs, and humans.Multiple-dose pharmacokinetics of ofloxacin in serum, saliva, and skin blister fluid of healthy volunteersPurification of Citrobacter freundii DNA gyrase and inhibition by quinolonesTreatment of experimental Salmonella typhimurium infection in mice with fleroxacinFleroxacin (Ro 23-6240) distribution in canine prostatic tissue and fluids.In vitro activity of DR-3355, an optically active ofloxacinPharmacokinetics of a new quinolone, AM-833, in mice, rats, rabbits, dogs, and monkeysMIC quality control guidelines for Haemophilus susceptibility tests using cefdinir (FK482), cefepime, cefetamet, cefpirome, ceftibuten, fleroxacin, temafloxacin, clarithromycin, RP59500, and trospectomycin.Disk diffusion quality control guidelines for Haemophilus susceptibility tests using cefdinir, CI-960, fleroxacin, temafloxacin, and trospectomycin.Interpretive criteria for susceptibility testing of CI-960 (PD127391, AM-1091), fleroxacin, lomefloxacin, and temafloxacin against Neisseria gonorrhoeae, including drug stability in GC agar medium.MIC and disk diffusion quality control guidelines for Neisseria gonorrhoeae susceptibility tests of cefdinir, cefetamet, CI-960, fleroxacin, lomefloxacin, and temafloxacinCharacterization of the porins of Campylobacter jejuni and Campylobacter coli and implications for antibiotic susceptibilityClinical isolate of Citrobacter freundii highly resistant to new quinolones.Quinolone resistance in clinical isolates of Serratia marcescensInhibitory effects of quinolones on DNA gyrase of Escherichia coli and topoisomerase II of fetal calf thymus.Pharmacokinetics and tissue penetration of Ro 23-6240, a new trifluoroquinolone.Mutations producing resistance to norfloxacin in Pseudomonas aeruginosa.Isolation and characterization of norfloxacin-resistant mutants of Escherichia coli K-12.Inhibitory effects of ciprofloxacin and sparfloxacin on DNA gyrase purified from fluoroquinolone-resistant strains of methicillin-resistant Staphylococcus aureus.Pharmacokinetics of 18F-labeled fleroxacin in rabbits with Escherichia coli infections, studied with positron emission tomography.In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone.Comparative in vitro activity of RO 23-6240 (fleroxacin), a new 4-quinolone derivative.Interpretive criteria for CI-960, fleroxacin and temafloxacin susceptibility tests with Haemophilus influenzae.In vitro activity of Ro 24-6392, a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.
P2860
Q24671010-9880EB24-EE0E-48A3-8934-52B80DE98D00Q28326997-522EB7B4-B924-4F0F-B8DB-2D75B53276ABQ33742804-9775BA47-AD07-4619-9BD4-39AB89AFA369Q34681603-40E24B7D-7D02-4FB8-8C52-CD30CAFFD574Q35245673-0607EEB4-05CC-40F3-85BD-0D8AB0B7F0E2Q35245897-C694D5AB-B659-4CC7-870F-06AD2D307130Q35289324-D6A1F0DD-BC10-454F-8614-5BE28DFB5D69Q35307223-CB6B8200-2DE0-4582-BD10-5739D6BEB30CQ35540757-CE1072F5-9B06-4BAC-B2B4-C82988786149Q35563775-1D10A307-2A90-4679-BF10-2B08B33D9BCEQ35651641-D5093DC9-71FC-42B0-AB33-5B22660E7E73Q37115080-BAD84AE9-0582-4E47-8536-FA0BF6513C8AQ37118146-1432AF10-D3AF-47AF-A196-F5E3840D6924Q37120085-BA253FCD-74FD-4196-A046-FA52E284BF82Q37120847-EE78AD5B-54E6-40C4-93DC-8F929FA7E85FQ38272526-72DD8435-5434-4BBB-ABEA-BACB683ED927Q39818366-A2DC89BF-99C6-47BA-BEFC-52AADE1BF5A7Q39819300-E7B5C48C-B6A6-426D-AC79-1E4E36F28DBFQ39820165-8D390553-9216-4252-A43E-8D7E4F8AAA32Q39827591-5A1D8E5D-A6BE-461D-BEB8-32AFD6B8E66BQ39827996-C87A0AE4-50C4-428B-9849-0522FA1A5504Q39851366-8242BDC6-AFA0-4398-9BC4-5BB1D04110F5Q40087982-03D10665-0632-4F64-9ABE-494FFD676E07Q40088633-44319955-6030-46F6-A28A-7BC636663D27Q40285332-C762E58A-FDF7-4C5C-A53D-3F9B3FB2DC33Q45245312-343D325E-4F78-4AD8-B21D-78DF7EB49998Q54271673-C3EA37CC-639C-46A2-BEFB-7C784284EC3AQ54322072-47275534-7778-4FAA-B967-914F55253FEC
P2860
In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivative
description
1986 nî lūn-bûn
@nan
1986 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1986 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1986年の論文
@ja
1986年論文
@yue
1986年論文
@zh-hant
1986年論文
@zh-hk
1986年論文
@zh-mo
1986年論文
@zh-tw
1986年论文
@wuu
name
In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivative
@ast
In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivative
@en
In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivative
@nl
type
label
In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivative
@ast
In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivative
@en
In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivative
@nl
prefLabel
In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivative
@ast
In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivative
@en
In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivative
@nl
P2093
P2860
P356
P1476
In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivative
@en
P2093
P2860
P304
P356
10.1128/AAC.29.6.1059
P407
P577
1986-06-01T00:00:00Z